Last update 22 Dec 2024

PE-0116

Overview

Basic Info

Drug Type
Monoclonal antibody
Synonyms
HY000101, PE 0116, PE-0116
+ [1]
Target
4-1BB
Mechanism
4-1BB agonists(Tumor necrosis factor receptor superfamily member 9 agonists), ADCC(Antibody-dependent cell-mediated cytotoxicity (ADCC) effects)
Therapeutic Areas
Neoplasms
Active Indication
Advanced Malignant Solid Neoplasm
Inactive Indication-
Originator Organization
Shanghai HyaMab Biotechnology Co., Ltd.Shanghai HyaMab Biotechnology Co., Ltd.
Active Organization
Shanghai HyaMab Biotechnology Co., Ltd.Shanghai HyaMab Biotechnology Co., Ltd.
Inactive Organization-
Drug Highest PhasePhase 1/2
First Approval Date-
Regulation-
Login to view timeline

Related

5
Clinical Trials associated with PE-0116
NCT05801237 / RecruitingPhase 1/2
A Phase Ib/II Clinical Trial to Evaluate the Tolerability, Safety, Pharmacokinetics and Preliminary Antitumor Activity of PE0116 and PE0105 Injection in Treatment of Patients With Advanced Solid Tumor
CTR20232109 / RecruitingPhase 1/2
一项评估PE0116联合PE0105注射液在晚期实体瘤患者中的耐受性、安全性和药代动力学特性以及初步有效性的Ib/II期临床研究
[Translation] A Phase Ib/II clinical study to evaluate the tolerability, safety, pharmacokinetic properties and preliminary efficacy of PE0116 combined with PE0105 injection in patients with advanced solid tumors
NCT06026501 / Not yet recruitingPhase 1/2
A Phase Ib/II Clinical Trial to Evaluate the Tolerability, Safety, Pharmacokinetics and Preliminary Antitumor Activity of PE0116 and PE0105 Injection in Treatment of Patients With Advanced Solid Tumor
100 Clinical Results associated with PE-0116
Login to view more data
100 Translational Medicine associated with PE-0116
Login to view more data
100 Patents (Medical) associated with PE-0116
Login to view more data
100 Deals associated with PE-0116
Login to view more data

R&D Status

10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Advanced Malignant Solid NeoplasmPhase 2
CN
Shanghai HyaMab Biotechnology Co., Ltd.Shanghai HyaMab Biotechnology Co., Ltd.
20 Sep 2023
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
CTR20201794 (ASCO2022)
ManualManual
Phase 1
Solid tumor
19
bsdtdawoap(szlubmeahz) = 1 g2 ascites, 1 g4 dyspnea, 1 g2 fever fhuazjfzou (zdkpilhvlt )
View more
Positive
02 Jun 2022
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
login
or
view full example data
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
login
or
view full example data
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
login
or
view full example data
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
login
or
view full example data
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
login
or
view full example data
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
login
or
view full example data
Understand key drug designations in just a few clicks with Synapse.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free